Inicio › Mieloma múltiple › Ohio › Cleveland
Ensayos clínicos de Mieloma múltiple en Cleveland, OH
14 estudios para Mieloma múltiple buscan participantes en centros de Cleveland y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
ReclutandoFase 3
- Cleveland Clinic, Cleveland
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
ReclutandoFase 2
- Cleveland Clinic, Cleveland
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
ReclutandoFase 3
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Main Campus, Cleveland
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 3
- Cleveland Clinic, Cleveland
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
ReclutandoEstudio observacional
- University Hospitals Seidman Cancer Center, Cleveland
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
ReclutandoFase 3
- Cleveland Clinic, Cleveland
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
ReclutandoFase 1
- Cleveland Clinic - Taussig Cancer Institute, Cleveland
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
ReclutandoFase 3
- Research Site, Cleveland
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ReclutandoFase 3
- Research Site, Cleveland
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
ReclutandoFase 2
- University Hospitals Cleveland Medical Center, Cleveland
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ReclutandoFase 3
- MetroHealth Medical Center, Cleveland
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
ReclutandoFase 3
- Research Site, Cleveland
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ReclutandoFase 1
- Cleveland Clinic, Cleveland
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
ReclutandoFase 1/2
- University Hospitals Cleveland, Cleveland
Más información sobre Mieloma múltiple en MedlinePlus
Ensayos de Mieloma múltiple en otras ciudades
- New York City, NY59 estudios
- Boston, MA45 estudios
- Atlanta, GA42 estudios
- Houston, TX39 estudios
- Durham, NC36 estudios
- Nashville, TN31 estudios
- Denver, CO26 estudios
- St. Louis, MO26 estudios
- Rochester, MN25 estudios
- Columbus, OH25 estudios
- Chicago, IL24 estudios
- Milwaukee, WI23 estudios
Otros estudios en Cleveland
- Cáncer de pulmón de células no pequeñas48 estudios
- Cáncer (todos los tipos)36 estudios
- Cáncer de seno33 estudios
- Fallo cardíaco31 estudios
- Cáncer metastásico30 estudios
- Cáncer de próstata30 estudios
- Cáncer de ovario29 estudios
- Cáncer de pulmón26 estudios
- Cáncer del colon y del recto25 estudios
- Leucemia mielógena aguda20 estudios
- Carcinoma de células escamosas de cabeza y cuello20 estudios
- Enfermedad cardiovascular20 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.